

## Valor Health Plan 2022 Formulary Addendum

**BvD – Part B vs. Part D, NF - Non-Formulary, PA1 - Prior Authorization for All Members,  
PA2 – Prior Authorization for New Starts Only, QL – Quantity Limit per 30 Days, ST - Step Therapy**

### 2022 FORMULARY CHANGES

Drug Name	Current Drug Tier	New Drug Tier	Reason For Change	Alternative Drug, Alternative Drug Tier
<b>EFFECTIVE 01/01/2022</b>				
Ayvakit Tablet 25 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Ayvakit Tablet 50 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
chlorproMAZINE HCl Concentrate 100 MG/ML Oral	NF	1 + PA2	Formulary Enhancement	N/A
chlorproMAZINE HCl Concentrate 30 MG/ML Oral	NF	1 + PA2	Formulary Enhancement	N/A
Clovique Capsule 250 MG Oral	1 + PA1	NF	CMS Required Deletion	N/A
Dupixent Solution Pen-Injector 200 MG/1.14ML Subcutaneous	NF	1 + PA1	Formulary Enhancement	N/A
Etravirine Tablet 100 MG Oral	NF	1	Formulary Enhancement	N/A
Etravirine Tablet 200 MG Oral	NF	1	Formulary Enhancement	N/A
Intelligence Tablet 100 MG Oral	1	NF	Formulary Update	etravirine tablet 100 MG Oral, 1
Intelligence Tablet 200 MG Oral	1	NF	Formulary Update	etravirine tablet 200 MG Oral, 1
Kaletra Tablet 100-25 MG Oral	1	NF	Formulary Update	lopinavir-ritonavir tablet 100-25 mg oral, 1
Kaletra Tablet 200-50 MG Oral	1	NF	Formulary Update	lopinavir-ritonavir tablet 200-50 mg oral, 1
Kloxxado Liquid 8 MG/0.1ML Nasal	NF	1	Formulary Enhancement	N/A
Lopinavir-Ritonavir Tablet 100-25 MG Oral	NF	1	Formulary Enhancement	N/A
Lopinavir-Ritonavir Tablet 200-50 MG Oral	NF	1	Formulary Enhancement	N/A
Lumakras Tablet 120 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Potassium Chloride Crys ER Tablet Extended Release 15 MEQ Oral	NF	1	Formulary Enhancement	N/A
Rezurock Tablet 200 MG Oral	NF	1 + PA1	Formulary Enhancement	N/A
SUNItinib Malate Capsule 12.5 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A

**H1119\_FORMCHNGS22\_C**  
**Formulary ID: 22382, Version 13**  
**Last Updated: 05/27/2022**  
**Effective date: 06/01/2022**

## Valor Health Plan 2022 Formulary Addendum

**BvD – Part B vs. Part D, NF - Non-Formulary, PA1 - Prior Authorization for All Members,  
PA2 – Prior Authorization for New Starts Only, QL – Quantity Limit per 30 Days, ST - Step Therapy**

### 2022 FORMULARY CHANGES

Drug Name	Current Drug Tier	New Drug Tier	Reason For Change	Alternative Drug, Alternative Drug Tier
SUNItinib Malate Capsule 25 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
SUNItinib Malate Capsule 37.5 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
SUNItinib Malate Capsule 50 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Sutent CAPSULE 12.5 MG ORAL	1 + PA2	NF	Formulary Update	sUNItinib malate Capsule 12.5 mg oral, 1 + PA2
Sutent CAPSULE 25 MG ORAL	1 + PA2	NF	Formulary Update	sUNItinib malate capsule 25 mg oral, 1 + PA2
Sutent CAPSULE 37.5 MG ORAL	1 + PA2	NF	Formulary Update	sUNItinib malate capsule 37.5 mg oral, 1 + PA2
Sutent CAPSULE 50 MG ORAL	1 + PA2	NF	CMS Required Deletion	SUNItinib Malate Capsule 50 MG Oral, 1 + PA2
Theophylline ER Tablet Extended Release 12 Hour 450 MG Oral	NF	1	Formulary Enhancement	N/A
Trikafta Tablet Therapy Pack 50-25-37.5 & 75 MG Oral	NF	1 + PA1	Formulary Enhancement	N/A
TriLyte Solution Reconstituted 420 GM Oral	1	NF	CMS Required Deletion	N/A
Xcopri (250 MG Daily Dose) Tablet Therapy Pack 50 & 200 MG Oral	1 + QL 56/28	NF	CMS Required Deletion	N/A
Xofluza (40 MG Dose) Tablet Therapy Pack 1 x 40 MG Oral	NF	1	Formulary Enhancement	N/A
Xofluza (40 MG Dose) Tablet Therapy Pack 2 x 20 MG Oral	1	NF	CMS Required Deletion	N/A
Xofluza (80 MG Dose) Tablet Therapy Pack 2 x 40 MG Oral	1	NF	CMS Required Deletion	N/A
<b>EFFECTIVE 02/01/2022</b>				

**H1119\_FORMCHNGS22\_C**  
**Formulary ID: 22382, Version 13**  
**Last Updated: 05/27/2022**  
**Effective date: 06/01/2022**

## Valor Health Plan 2022 Formulary Addendum

**BvD – Part B vs. Part D, NF - Non-Formulary, PA1 - Prior Authorization for All Members,  
PA2 – Prior Authorization for New Starts Only, QL – Quantity Limit per 30 Days, ST - Step Therapy**

### 2022 FORMULARY CHANGES

Drug Name	Current Drug Tier	New Drug Tier	Reason For Change	Alternative Drug, Alternative Drug Tier
Afinitor Disperz TABLET SOLUBLE 2 MG ORAL	1 + QL 30 + PA2	NF	Formulary Update	everolimus tablet soluble 2 mg oral, 1 + QL 30 + PA2
Afinitor Disperz TABLET SOLUBLE 3 MG ORAL	1 + QL 30 + PA2	NF	Formulary Update	everolimus tablet soluble 3 mg oral, 1 + QL 30 + PA2
Afinitor Disperz TABLET SOLUBLE 5 MG ORAL	1 + QL 60 + PA2	NF	Formulary Update	everolimus tablet soluble 5 mg oral, 1 + QL 60 + PA2
Afinitor TABLET 10 MG ORAL	1 + QL 30 + PA2	NF	Formulary Update	everolimus tablet 10 mg oral, 1 + QL 30 + PA2
azaTHIOprine Tablet 100 MG Oral	NF	1 + BvD	Formulary Enhancement	N/A
azaTHIOprine Tablet 75 MG Oral	NF	1 + BvD	Formulary Enhancement	N/A
Bystolic Tablet 10 MG Oral	1	NF	Formulary Update	nebivolol hcl tablet 10 mg oral, 1
Bystolic Tablet 2.5 MG Oral	1	NF	Formulary Update	nebivolol hcl tablet 2.5 mg oral, 1
Bystolic Tablet 20 MG Oral	1	NF	Formulary Update	nebivolol hcl tablet 20 mg oral, 1
Bystolic Tablet 5 MG Oral	1	NF	Formulary Update	nebivolol hcl tablet 5 mg oral, 1
Chantix Tablet 0.5 MG Oral	1	NF	Formulary Update	varenicline tartrate tablet 0.5 mg oral, 1
Chantix Tablet 1 MG Oral	1	NF	Formulary Update	varenicline tartrate tablet 1 mg oral, 1
Cosentyx Solution Prefilled Syringe 75 MG/0.5ML Subcutaneous	NF	1 + PA2	Formulary Enhancement	N/A
Cyclafem 1/35 Tablet 1-35 MG-MCG Oral	1	NF	CMS Required Deletion	N/A
Cyclafem 7/7/7 Tablet 0.5/0.75/1-35 MG-MCG Oral	1	NF	CMS Required Deletion	N/A

**H1119\_FORMCHNGS22\_C**  
**Formulary ID: 22382, Version 13**  
**Last Updated: 05/27/2022**  
**Effective date: 06/01/2022**

## Valor Health Plan 2022 Formulary Addendum

**BvD – Part B vs. Part D, NF - Non-Formulary, PA1 - Prior Authorization for All Members,  
PA2 – Prior Authorization for New Starts Only, QL – Quantity Limit per 30 Days, ST - Step Therapy**

### 2022 FORMULARY CHANGES

Drug Name	Current Drug Tier	New Drug Tier	Reason For Change	Alternative Drug, Alternative Drug Tier
Dextroamphetamine Sulfate Tablet 15 MG Oral	NF	1	Formulary Enhancement	N/A
Dextroamphetamine Sulfate Tablet 20 MG Oral	NF	1	Formulary Enhancement	N/A
Dextroamphetamine Sulfate Tablet 30 MG Oral	NF	1	Formulary Enhancement	N/A
Everolimus Tablet 10 MG Oral	NF	1 + QL 30 + PA2	Formulary Enhancement	N/A
Everolimus Tablet Soluble 2 MG Oral	NF	1 + QL 30 + PA2	Formulary Enhancement	N/A
Everolimus Tablet Soluble 3 MG Oral	NF	1 + QL 30 + PA2	Formulary Enhancement	N/A
Everolimus Tablet Soluble 5 MG Oral	NF	1 + QL 60 + PA2	Formulary Enhancement	N/A
Invega Hafyera Suspension Prefilled Syringe 1092 MG/3.5ML Intramuscular	NF	1 + QL 3.5/180	Formulary Enhancement	N/A
Invega Hafyera Suspension Prefilled Syringe 1560 MG/5ML Intramuscular	NF	1 + QL 5/180	Formulary Enhancement	N/A
Lybalvi Tablet 10-10 MG Oral	NF	1 + QL 30 + PA2	Formulary Enhancement	N/A
Lybalvi Tablet 15-10 MG Oral	NF	1 + QL 30 + PA2	Formulary Enhancement	N/A
Lybalvi Tablet 20-10 MG Oral	NF	1 + QL 30 + PA2	Formulary Enhancement	N/A
Lybalvi Tablet 5-10 MG Oral	NF	1 + QL 30 + PA2	Formulary Enhancement	N/A
Myrbetriq Suspension Reconstituted ER 8 MG/ML Oral	NF	1	Formulary Enhancement	N/A
Nebivolol HCl Tablet 10 MG Oral	NF	1	Formulary Enhancement	N/A
Nebivolol HCl Tablet 2.5 MG Oral	NF	1	Formulary Enhancement	N/A
Nebivolol HCl Tablet 20 MG Oral	NF	1	Formulary Enhancement	N/A
Nebivolol HCl Tablet 5 MG Oral	NF	1	Formulary Enhancement	N/A
Panretin Gel 0.1 % External	NF	1 + PA2	Formulary Enhancement	N/A

**H1119\_FORMCHNGS22\_C**

**Formulary ID: 22382, Version 13**

**Last Updated: 05/27/2022**

**Effective date: 06/01/2022**

## Valor Health Plan 2022 Formulary Addendum

**BvD – Part B vs. Part D, NF - Non-Formulary, PA1 - Prior Authorization for All Members,  
PA2 – Prior Authorization for New Starts Only, QL – Quantity Limit per 30 Days, ST - Step Therapy**

### 2022 FORMULARY CHANGES

Drug Name	Current Drug Tier	New Drug Tier	Reason For Change	Alternative Drug, Alternative Drug Tier
PARoxetine HCl Suspension 10 MG/5ML Oral	NF	1 + QL 900	Formulary Enhancement	N/A
Paxil SUSPENSION 10 MG/5ML ORAL	1 + QL 900	NF	Formulary Update	paroxetine hcl suspension 10 mg/5ml oral, 1 + QL 900
Pentacel Suspension Reconstituted Intramuscular	NF	1	Formulary Enhancement	N/A
Proparacaine HCl Solution 0.5 % Ophthalmic	1	NF	CMS Required Deletion	N/A
Sertraline HCl Capsule 150 MG Oral	NF	1	Formulary Enhancement	N/A
Sertraline HCl Capsule 200 MG Oral	NF	1	Formulary Enhancement	N/A
Tavneos Capsule 10 MG Oral	NF	1 + PA1	Formulary Enhancement	N/A
Truseltiq (100MG Daily Dose) Capsule Therapy Pack 100 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Truseltiq (125MG Daily Dose) Capsule Therapy Pack 100 & 25 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Truseltiq (50MG Daily Dose) Capsule Therapy Pack 25 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Truseltiq (75MG Daily Dose) Capsule Therapy Pack 25 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Varenicline Tartrate Tablet 0.5 MG Oral	NF	1	Formulary Enhancement	N/A
Varenicline Tartrate Tablet 1 MG Oral	NF	1	Formulary Enhancement	N/A
Welireg Tablet 40 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Xofluza (80 MG Dose) Tablet Therapy Pack 1 x 80 MG Oral	NF	1	Formulary Enhancement	N/A
Xpovio (100 MG Once Weekly) Tablet Therapy Pack 20 MG Oral	1 + PA2	NF	CMS Required Deletion	N/A
Xpovio (40 MG Once Weekly) Tablet Therapy Pack 20 MG Oral	1 + PA2	NF	CMS Required Deletion	N/A
Xpovio (40 MG Twice Weekly) Tablet Therapy Pack 20 MG Oral	1 + PA2	NF	CMS Required Deletion	N/A

**H1119\_FORMCHNGS22\_C**

**Formulary ID: 22382, Version 13**

**Last Updated: 05/27/2022**

**Effective date: 06/01/2022**

## Valor Health Plan 2022 Formulary Addendum

**BvD – Part B vs. Part D, NF - Non-Formulary, PA1 - Prior Authorization for All Members,  
PA2 – Prior Authorization for New Starts Only, QL – Quantity Limit per 30 Days, ST - Step Therapy**

<b>2022 FORMULARY CHANGES</b>				
Drug Name	Current Drug Tier	New Drug Tier	Reason For Change	Alternative Drug, Alternative Drug Tier
Xpovio (60 MG Once Weekly) Tablet Therapy Pack 20 MG Oral	1 + PA2	NF	CMS Required Deletion	N/A
Xpovio (80 MG Once Weekly) Tablet Therapy Pack 20 MG Oral	1 + PA2	NF	CMS Required Deletion	N/A
<b>EFFECTIVE 03/01/2022</b>				
Besremi Solution Prefilled Syringe 500 MCG/ML Subcutaneous	NF	1 + PA2	Formulary Enhancement	N/A
Breztri Aerosphere Aerosol 160-9-4.8 MCG/ACT Inhalation	NF	1	Formulary Enhancement	N/A
Dupixent Solution Prefilled Syringe 100 MG/0.67ML Subcutaneous	NF	1 + PA1	Formulary Enhancement	N/A
Eprontia Solution 25 MG/ML Oral	NF	1	Formulary Enhancement	N/A
Everolimus Tablet 1 MG Oral	NF	1 + BvD	Formulary Enhancement	N/A
Exkivity Capsule 40 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Hydroxychloroquine Sulfate Tablet 100 MG Oral	NF	1	Formulary Enhancement	N/A
Hydroxychloroquine Sulfate Tablet 300 MG Oral	NF	1	Formulary Enhancement	N/A
Hydroxychloroquine Sulfate Tablet 400 MG Oral	NF	1	Formulary Enhancement	N/A
Ivermectin TABLET 3 MG ORAL	1	1 + PA2	Formulary Update	N/A
Livmarli Solution 9.5 MG/ML Oral	NF	1 + PA1	Formulary Enhancement	N/A
Livtency Tablet 200 MG Oral	NF	1 + PA1	Formulary Enhancement	N/A
Morphine Sulfate ER Capsule Extended Release 24 Hour 40 MG Oral	1	NF	CMS Required Deletion	N/A
Naloxone HCl Liquid 4 MG/0.1ML Nasal	NF	1	Formulary Enhancement	N/A
Nylia 1/35 Tablet 1-35 MG-MCG Oral	NF	1	Formulary Enhancement	N/A
Scemblix Tablet 20 MG Oral	NF	1 + QL 60 + PA2	Formulary Enhancement	N/A
Scemblix Tablet 40 MG Oral	NF	1 + QL 300 + PA2	Formulary Enhancement	N/A

**H1119\_FORMCHNGS22\_C**  
**Formulary ID: 22382, Version 13**  
**Last Updated: 05/27/2022**  
**Effective date: 06/01/2022**

## Valor Health Plan 2022 Formulary Addendum

**BvD – Part B vs. Part D, NF - Non-Formulary, PA1 - Prior Authorization for All Members,  
PA2 – Prior Authorization for New Starts Only, QL – Quantity Limit per 30 Days, ST - Step Therapy**

### 2022 FORMULARY CHANGES

Drug Name	Current Drug Tier	New Drug Tier	Reason For Change	Alternative Drug, Alternative Drug Tier
Ticovac Suspension Prefilled Syringe 2.4 MCG/0.5ML Intramuscular	NF	1	Formulary Enhancement	N/A
Vancomycin HCl Solution Reconstituted 250 MG Intravenous	1	NF	CMS Required Deletion	N/A
Zarah Tablet 3-0.03 MG Oral	1	NF	CMS Required Deletion	N/A
Zortress Tablet 1 MG Oral	1 + BvD	NF	Formulary Update	everolimus tablet 1 MG Oral, 1 + BvD
<b>EFFECTIVE 04/01/2022</b>				
Accutane Capsule 10 MG Oral	NF	1	Formulary Enhancement	N/A
Biktarvy Tablet 30-120-15 MG Oral	NF	1	Formulary Enhancement	N/A
Brimonidine Tartrate-Timolol Solution 0.2-0.5 % Ophthalmic	NF	1	Formulary Enhancement	N/A
Bylvay (Pellets) Capsule Sprinkle 200 MCG Oral	NF	1 + PA1	Formulary Enhancement	N/A
Bylvay Capsule 1200 MCG Oral	NF	1 + PA1	Formulary Enhancement	N/A
Bylvay Capsule 400 MCG Oral	NF	1 + PA1	Formulary Enhancement	N/A
Desogestrel-Ethinyl Estradiol Tablet 0.15-30 MG-MCG Oral	NF	1	Formulary Enhancement	N/A
Hepatamine Solution 8 % Intravenous	1 + BvD	NF	CMS Required Deletion	N/A
Intron A Solution 6000000 UNIT/ML Injection	1 + PA2	NF	CMS Required Deletion	N/A
Intron A Solution 10000000 UNIT/ML Injection	1 + PA2	NF	CMS Required Deletion	N/A
K-Tab Tablet Extended Release 8 MEQ Oral	1	NF	CMS Required Deletion	N/A
MethylPREDNISolone Acetate Suspension 80 MG/ML Injection	NF	1	Formulary Enhancement	N/A
Tri-Previfem Tablet 0.18/0.215/0.25 MG-35 MCG Oral	1	NF	CMS Required Deletion	N/A
VariZIG Solution 125 UNIT/1.2ML Intramuscular	1 + PA1	NF	CMS Required Deletion	N/A
<b>EFFECTIVE 05/01/2022</b>				
Adapalene Gel 0.1 % External	1 + PA1	NF	CMS Required Deletion	N/A

**H1119\_FORMCHNGS22\_C**  
**Formulary ID: 22382, Version 13**  
**Last Updated: 05/27/2022**  
**Effective date: 06/01/2022**

## Valor Health Plan 2022 Formulary Addendum

**BvD – Part B vs. Part D, NF - Non-Formulary, PA1 - Prior Authorization for All Members,  
PA2 – Prior Authorization for New Starts Only, QL – Quantity Limit per 30 Days, ST - Step Therapy**

### 2022 FORMULARY CHANGES

Drug Name	Current Drug Tier	New Drug Tier	Reason For Change	Alternative Drug, Alternative Drug Tier
Aminosyn-PF Solution 7 % Intravenous	1 + BvD	NF	CMS Required Deletion	N/A
amLODIPine-Valsartan-HCTZ Tablet 10-160-12.5 MG Oral	1	NF	CMS Required Deletion	N/A
amLODIPine-Valsartan-HCTZ Tablet 10-160-25 MG Oral	1	NF	CMS Required Deletion	N/A
amLODIPine-Valsartan-HCTZ Tablet 10-320-25 MG Oral	1	NF	CMS Required Deletion	N/A
amLODIPine-Valsartan-HCTZ Tablet 5-160-12.5 MG Oral	1	NF	CMS Required Deletion	N/A
amLODIPine-Valsartan-HCTZ Tablet 5-160-25 MG Oral	1	NF	CMS Required Deletion	N/A
Carbaglu Tablet 200 MG Oral	1 + PA1	NF	Formulary Update	carglumic acid tablet 200 mg oral, 1 + PA1
Carglumic Acid Tablet 200 MG Oral	NF	1 + PA1	Formulary Enhancement	N/A
Cefuroxime Sodium Solution Reconstituted 7.5 GM Injection	1	NF	CMS Required Deletion	N/A
Citalopram Hydrobromide Capsule 30 MG Oral	NF	1	Formulary Enhancement	N/A
Glycopyrrolate Solution 1 MG/5ML Oral	NF	1	Formulary Enhancement	N/A
Maraviroc Tablet 150 MG Oral	NF	1	Formulary Enhancement	N/A
Maraviroc Tablet 300 MG Oral	NF	1	Formulary Enhancement	N/A
Mavyret Packet 50-20 MG Oral	NF	1 + PA1	Formulary Enhancement	N/A
Moxeza Solution 0.5 % Ophthalmic	1	NF	CMS Required Deletion	N/A
Ondansetron HCl Solution 4 MG/2ML Injection	1 + QL 360 + BvD	1 + BvD	Formulary Enhancement	N/A
Ondansetron HCl Solution 4 MG/5ML Oral	1 + QL 450 + BvD	1 + BvD	Formulary Enhancement	N/A
Ondansetron HCl Solution 40 MG/20ML Injection	1 + QL 360 + BvD	1 + BvD	Formulary Enhancement	N/A
Ondansetron HCl Tablet 24 MG Oral	1 + QL 30 + BvD	1 + BvD	Formulary Enhancement	N/A

**H1119\_FORMCHNGS22\_C**  
**Formulary ID: 22382, Version 13**  
**Last Updated: 05/27/2022**  
**Effective date: 06/01/2022**



## Valor Health Plan 2022 Formulary Addendum

**BvD – Part B vs. Part D, NF - Non-Formulary, PA1 - Prior Authorization for All Members,  
PA2 – Prior Authorization for New Starts Only, QL – Quantity Limit per 30 Days, ST - Step Therapy**

### 2022 FORMULARY CHANGES

Drug Name	Current Drug Tier	New Drug Tier	Reason For Change	Alternative Drug, Alternative Drug Tier
Ondansetron HCl Tablet 4 MG Oral	1 + QL 90 + BvD	1 + BvD	Formulary Enhancement	N/A
Ondansetron HCl Tablet 8 MG Oral	1 + QL 90 + BvD	1 + BvD	Formulary Enhancement	N/A
Ondansetron Tablet Dispersible 4 MG Oral	1 + QL 90 + BvD	1 + BvD	Formulary Enhancement	N/A
Ondansetron Tablet Dispersible 8 MG Oral	1 + QL 90 + BvD	1 + BvD	Formulary Enhancement	N/A
Rinvoq Tablet Extended Release 24 Hour 30 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Selzentry Tablet 150 MG Oral	1	NF	Formulary Update	maraviroc tablet 150 mg oral, 1
Selzentry Tablet 300 MG Oral	1	NF	Formulary Update	maraviroc tablet 300 mg oral, 1
Talzenna Capsule 0.5 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Talzenna Capsule 0.75 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Xarelto Suspension Reconstituted 1 MG/ML Oral	NF	1	Formulary Enhancement	N/A
<b>EFFECTIVE 06/01/2022</b>				
Aztreonam Solution Reconstituted 2 GM Injection	NF	1	Formulary Enhancement	N/A
Betaine Powder Oral	NF	1	Formulary Enhancement	N/A
Cystadane Powder Oral	1	NF	Formulary Update	betaine powder oral, 1
Farydak Capsule 10 MG Oral	1 + PA2	NF	CMS Required Deletion	N/A
Farydak Capsule 15 MG Oral	1 + PA2	NF	CMS Required Deletion	N/A
Farydak Capsule 20 MG Oral	1 + PA2	NF	CMS Required Deletion	N/A
Fluoroplex Cream 1 % External	1	NF	CMS Required Deletion	N/A
GaviLyte-N with Flavor Pack SOLUTION RECONSTITUTED 420 GM ORAL	1	NF	CMS Required Deletion	N/A
Gvoke Kit Solution 1 MG/0.2ML Subcutaneous	NF	1	Formulary Enhancement	N/A

**H1119\_FORMCHNGS22\_C**  
**Formulary ID: 22382, Version 13**  
**Last Updated: 05/27/2022**  
**Effective date: 06/01/2022**

## Valor Health Plan 2022 Formulary Addendum

**BvD – Part B vs. Part D, NF - Non-Formulary, PA1 - Prior Authorization for All Members,  
PA2 – Prior Authorization for New Starts Only, QL – Quantity Limit per 30 Days, ST - Step Therapy**

### 2022 FORMULARY CHANGES

Drug Name	Current Drug Tier	New Drug Tier	Reason For Change	Alternative Drug, Alternative Drug Tier
Invega Trinza Suspension Prefilled Syringe 273 MG/0.88ML Intramuscular	1 + QL 0.875/90	1 + QL 0.88/90	Formulary Enhancement	N/A
Invega Trinza Suspension Prefilled Syringe 410 MG/1.32ML Intramuscular	1 + QL 1.315/90	1 + QL 1.32/90	Formulary Enhancement	N/A
Invega Trinza Suspension Prefilled Syringe 819 MG/2.63ML Intramuscular	1 + QL 2.625/90	1 + QL 2.63/90	Formulary Enhancement	N/A
Invirase Tablet 500 MG Oral	1	NF	CMS Required Deletion	N/A
Kinrix Suspension Intramuscular	1	NF	CMS Required Deletion	N/A
Lacosamide Tablet 100 MG Oral	NF	1 + QL 60	Formulary Enhancement	N/A
Lacosamide Tablet 150 MG Oral	NF	1 + QL 60	Formulary Enhancement	N/A
Lacosamide Tablet 200 MG Oral	NF	1 + QL 60	Formulary Enhancement	N/A
Lacosamide Tablet 50 MG Oral	NF	1 + QL 60	Formulary Enhancement	N/A
Lenalidomide Capsule 10 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Lenalidomide Capsule 15 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Lenalidomide Capsule 25 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Lenalidomide Capsule 5 MG Oral	NF	1 + PA2	Formulary Enhancement	N/A
Phexxi Gel 1.8-1-0.4 % Vaginal	NF	1	Formulary Enhancement	N/A
Pyrukynd Tablet 20 MG Oral	NF	1 + QL 56/28 + PA1	Formulary Enhancement	N/A
Pyrukynd Tablet 5 MG Oral	NF	1 + QL 56/28 + PA1	Formulary Enhancement	N/A
Pyrukynd Tablet 50 MG Oral	NF	1 + QL 56/28 + PA1	Formulary Enhancement	N/A
Pyrukynd Taper Pack Tablet Therapy Pack 5 MG Oral	NF	1 + QL 7/7 + PA1	Formulary Enhancement	N/A
Pyrukynd Taper Pack Tablet Therapy Pack 7 x 20 MG & 7 x 5 MG Oral	NF	1 + QL 14/14 + PA1	Formulary Enhancement	N/A
Pyrukynd Taper Pack Tablet Therapy Pack 7 x 50 MG & 7 x 20 MG Oral	NF	1 + QL 14/14 + PA1	Formulary Enhancement	N/A
Quadracel Suspension Intramuscular (58 UNT/ML)	NF	1	Formulary Enhancement	N/A

**H1119\_FORMCHNGS22\_C**

**Formulary ID: 22382, Version 13**

**Last Updated: 05/27/2022**

**Effective date: 06/01/2022**

## Valor Health Plan 2022 Formulary Addendum

**BvD – Part B vs. Part D, NF - Non-Formulary, PA1 - Prior Authorization for All Members,  
PA2 – Prior Authorization for New Starts Only, QL – Quantity Limit per 30 Days, ST - Step Therapy**

<b>2022 FORMULARY CHANGES</b>				
<b>Drug Name</b>	<b>Current Drug Tier</b>	<b>New Drug Tier</b>	<b>Reason For Change</b>	<b>Alternative Drug, Alternative Drug Tier</b>
Revlimid Capsule 10 MG Oral	1 + PA2	NF	Formulary Update	lenalidomide capsule 10 mg oral, 1 + PA2
Revlimid Capsule 15 MG Oral	1 + PA2	NF	Formulary Update	lenalidomide capsule 15 mg oral, 1 + PA2
Revlimid Capsule 25 MG Oral	1 + PA2	NF	Formulary Update	lenalidomide capsule 25 mg oral, 1 + PA2
Revlimid Capsule 5 MG Oral	1 + PA2	NF	Formulary Update	lenalidomide capsule 5 mg oral, 1 + PA2
Tekturna HCT Tablet 150-12.5 MG Oral	1	NF	CMS Required Deletion	N/A
Tekturna HCT Tablet 150-25 MG Oral	1	NF	CMS Required Deletion	N/A
Temixys Tablet 300-300 MG Oral	1	NF	CMS Required Deletion	N/A
Vimpat Tablet 100 MG Oral	1 + QL 60	NF	Formulary Update	lacosamide tablet 100 mg oral, 1 + QL 60
Vimpat Tablet 150 MG Oral	1 + QL 60	NF	Formulary Update	lacosamide tablet 150 mg oral, 1 + QL 60
Vimpat Tablet 200 MG Oral	1 + QL 60	NF	Formulary Update	lacosamide tablet 200 mg oral, 1 + QL 60
Vimpat Tablet 50 MG Oral	1 + QL 60	NF	Formulary Update	lacosamide tablet 50 mg oral, 1 + QL 60

**H1119\_FORMCHNGS22\_C**  
**Formulary ID: 22382, Version 13**  
**Last Updated: 05/27/2022**  
**Effective date: 06/01/2022**